1
Nalin Subasinghe, Ehab Khalil, Kristi A Leonard, Farah Ali, Heather Hufnagel, Jeremy M Travins, Shelley K Ballentine, Kenneth T Wilson, Maxwell D Cummings, Wenxi Pan, Joan Gushue, Sanath Meegalla, Mark Wall, Jinsheng Chen, Jonathan M Rudolph, Hui Huang: Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions. 3 Dimensional Pharmaceuticals, November 21, 2006: US07138530 (11 worldwide citation)

Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula (I) or a solvate, hydrate or pharmac ...


2
Nalin Subasinghe, Ehab Khalil, Kristi Leonard, Farah Ali, Heather Rae Hufnagel, Jeremy M Travins, Shelley K Ballentine, Kenneth T Wilson, Maxwell D Cummings, Wenxi Pan, Joan Gushue, Sanath Meegalla, Mark Wall, Jinsheng Chen, M Jonathan Rudolph, Hui Huang: Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions. 3 Dimensional Pharmaceuticals, September 19, 2006: US07109354 (6 worldwide citation)

Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a solvate, hydrate or pharmaceu ...


3
Philip A Cole, Ehab Khalil: Inhibitors of sorotonin N-acetyltransferase. The Rockefeller University, Klauber & Jackson, November 23, 1999: US05990094 (4 worldwide citation)

This invention is directed to a compound having the formula I. ##STR1## This invention is directed to a pharmaceutical composition comprising a compound which inhibits serotonin N-acetyltransferase having the formula I and a pharmaceutical acceptable carrier. The present invention relates to novel c ...


4
Tianbao Lu, Richard Alexander, Richard W Connors, Maxwell D Cummings, Robert A Galemmo, Heather Rae Hufnagel, Dana L Johnson, Ehab Khalil, Kristi A Leonard, Thomas P Markotan, Anna C Maroney, Jan L Sechler, Jeremy M Travins, Robert W Tuman: Triazolopyridazines as kinase modulators. Janssen Pharmaceutica, Rajiv S Shah, October 4, 2011: US08030305

The invention is directed to triazolopyridazine compounds of Formula I: where R1, R5, R6, R7, R8, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Me ...


5
Tianbao Lu, Richard Alexander, Richard W Connors, Maxwell D Cummings, Robert A Galemmo, Heather Rae Hufnagel, Dana L Johnson, Ehab Khalil, Kristi A Leonard, Thomas P Markotan, Anna C Maroney, Jan L Sechler, Jeremy M Travins, Robert W Tuman: Triazolopyridazine compounds. Janssen Pharmaceutica, Rajiv S Shah, May 8, 2012: US08173654

The invention is directed to triazolopyridazine compounds of Formula I: where R1, R5, R6, R7, R8, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Me ...


6
Nalin Subasinghe, Ehab Khalil, Farah Ali, Heather Rae Hufnagel, Shelley Ballentine, Jeremy M Travins, Kristi A Leonard, Roger F Bone: Conjugated complement cascade inhibitors. 3 Dimensional Pharmaceuticals, January 27, 2009: US07482376

The present invention is directed to conjugated complement cascade inhibitors, and a method of treating a patient using a conjugated complement cascade inhibitor.


7
Nalin Subasinghe, Ehab Khalil, Farah Ali, Heather Rae Hufnagel, Shelley Ballentine, Jeremy M Travins, Kristi A Leonard, Roger F Bone: Conjugated complement cascade inhibitors. Woodcock Washburn, January 6, 2005: US20050004031-A1

The present invention is directed to conjugated complement cascade inhibitors, and a method of treating a patient using a conjugated complement cascade inhibitor.


8
Tianbao Lu, Richard Alexander, Richard W Connors, Maxwell D Cummings, Robert A Galemmo, Heather Rae Hufnagel, Dana L Johnson, Ehab Khalil, Kristi A Leonard, Thomas P Markotan, Anna C Maroney, Jan L Sechler, Jeremy M Travins, Robert W Tuman: Triazolopyridazines as kinase modulators. Philip S Johnson, Johnson & Johnson, August 30, 2007: US20070203136-A1

The invention is directed to triazolopyridazine compounds of Formula I: where R1, R5, R6, R7, R8, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Me ...


9
Nalin Subasinghe, Ehab Khalil, Kristi Leonard, Farah Ali, Heather Rae Hufnagel, Jeremy M Travins, Shelley K Ballentine, Kenneth T Wilson, Maxwell D Cummings, Wenxi Pan, Joan Gushue, Sanath Meegalla, Mark Wall, Jinsheng Chen, M Jonathan Rudolph, Hui Huang: Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions. 3 Dimensional Pharmaceuticals, Sterne Kessler Goldstein & Fox Pllc, January 15, 2004: US20040009995-A1

Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I 1 or a solvate, hydrate or pharmac ...


10
Tianbao Lu, Richard Alexander, Richard W Connors, Maxwell D Cummings, Robert A Galemmo, Heather Rae Hufnagel, Dana L Johnson, Ehab Khalil, Kristi A Leonard, Thomas P Markotan, Anna C Maroney, Jan L Sechler, Jeremy M Travins, Robert W Tuman: Triazolopyridazines as kinase modulators. Philip S Johnson, Johnson & Johnson, April 16, 2009: US20090098181-A1

The invention is directed to triazolopyridazine compounds of Formula I: where R1, R5, R6, R7, R8, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Me ...